Healthcare Markets, Competition and Information

Introduction and context

Healthcare markets differ from ordinary consumer markets because illness is uncertain, clinical knowledge is specialized, payment is frequently separated from consumption, and decisions involve ethically significant consequences. A patient may not know whether treatment is necessary, an insurer may pay most of the bill, and a provider may simultaneously act as diagnostician, adviser and seller. These conditions make price an incomplete signal of value and create distinctive implications for efficiency, equity, quality and innovation.

Healthcare managers therefore need more than a conventional supply-and-demand model. They must understand market structure, the economics of uncertainty, information asymmetry, agency relationships, supplier-induced demand, transaction costs and consolidation. They must also interpret competition broadly: competition may occur through price, quality, access, convenience, reputation, technology and contractual design.

Learning objectives

By the end of this chapter, the learner should be able to:

1. Distinguish major healthcare market structures and predict their likely effects.
2. Explain how uncertainty, insurance and information asymmetry shape healthcare demand.
3. Analyse agency relationships, supplier-induced demand and transaction costs.
4. Evaluate consolidation and competition using price, access, quality and innovation criteria.
5. Apply economic reasoning to managerial, regulatory and governance decisions.

1. What is a healthcare market?

A market is an institutional arrangement through which buyers and sellers exchange goods or services. A healthcare market includes several linked markets rather than one unified market:

• Clinical service markets: hospitals, physician practices, laboratories, pharmacies and rehabilitation providers.
• Insurance markets: public and private purchasers that pool financial risk.
• Labour markets: physicians, nurses, pharmacists, technicians and managers.
• Technology and pharmaceutical markets: devices, medicines, software and diagnostic systems.
• Capital markets: financing for hospitals, clinics and health technology.

The relevant market must be defined carefully. A hospital may compete with nearby hospitals for inpatient care but face little competition for specialist cardiac surgery. Geographic boundaries depend on travel time, referral patterns, emergency access and transport infrastructure. Product boundaries depend on clinical substitutability: outpatient treatment may substitute for inpatient treatment in one condition but not another.

Healthcare demand is derived demand. Patients generally do not demand surgery, imaging or medication for their own sake; they demand improved health, functioning or survival. A simplified health-production relationship is:

where H is achieved health, M represents medical care, T is time and adherence, B is health-related behaviour, and E is the physical and social environment. The function is conceptual rather than a directly estimable law. It emphasizes that medical care is only one input into health and that its marginal benefit varies across patients.

2. Market structures in healthcare

Market structure describes the number and relative power of buyers and sellers, the degree of product differentiation, barriers to entry and the availability of information.

Perfect competition as a benchmark

In the textbook competitive model, price tends toward marginal cost, where marginal cost is the additional cost of producing one more unit. Economic profit attracts entry, while losses encourage exit. Healthcare rarely satisfies the model because services are differentiated, quality is difficult to observe, professional licensing restricts entry, and patients often do not choose providers solely on price.

The competitive benchmark remains useful. If a market has persistent high prices, weak quality and substantial barriers to entry, managers and regulators can ask whether competition is failing and whether better information, entry or purchasing arrangements could improve outcomes.

Differentiation and monopolistic competition

Providers differentiate through location, waiting time, technology, amenities, specialist reputation, continuity and perceived quality. Differentiation may benefit patients by supporting choice and innovation. It may also enable providers to charge more without proportional clinical benefit. A hospital’s brand is therefore not equivalent to measured value.

Oligopoly and strategic behaviour

In an oligopoly, each major provider anticipates rivals’ responses. A hospital’s acquisition of a specialist group may alter referral flows, insurer negotiations and competitors’ investment decisions. Prices may rise even without explicit collusion if rivals recognize that aggressive price competition would reduce everyone’s margins. Competition authorities therefore examine concentration, entry conditions, bargaining power and likely effects rather than relying only on the number of firms.

Monopoly and monopsony

A monopoly can arise from geography, economies of scale, exclusive technology, regulation or control of essential facilities. A rural hospital may be a local monopoly but still financially fragile because low population density limits volume. Market power does not automatically imply excessive profit.

A monopsony exists when one buyer has substantial purchasing power. A public payer may negotiate lower prices, potentially improving affordability. However, excessive buyer power may reduce provider participation, staffing, service availability or investment. The managerial question is not simply whether prices are low, but whether the arrangement sustains socially valuable capacity.

3. Demand, insurance and uncertainty

Healthcare needs are uncertain in timing, severity and financial consequence. Insurance converts uncertain large losses into more predictable premiums or taxes. If expected loss is pL, where p is the probability of illness and L is the financial loss, a risk-neutral person may be willing to pay approximately this expected loss. A risk-averse person may pay more because avoiding a severe loss has additional value. This is a conceptual comparison; actual premiums also include administration, capital costs, taxes, profit and insurer bargaining.

Insurance creates two important behavioural effects:

• Moral hazard: when coverage reduces the marginal price paid by the patient, use may increase or preventive effort may change.
• Risk selection: individuals with different expected costs may seek different plans, creating incentives for insurers to attract low-risk members or avoid high-risk members.

Insurance does not mean that all additional care is wasteful. A patient may consume more care because the effective price is lower, but some of that care can produce substantial health benefit. The policy challenge is to distinguish valuable risk protection from low-value utilization.

For a service with patient price P_p, insurer payment P_i and total price P, the accounting relationship is:

This identity describes payment shares, not economic cost or social value. A zero patient price does not imply zero resource cost.

4. Information asymmetry and quality

Information asymmetry exists when one party knows more relevant information than another. In healthcare, providers usually know more about diagnosis, prognosis, treatment alternatives and technical quality than patients. Insurers know more about contract terms and risk adjustment, while patients know more about symptoms, preferences and adherence than providers.

Adverse selection

Adverse selection occurs before contracting when one party has private information about risk. Individuals expecting high medical expenditure may be especially willing to buy generous insurance. If premiums reflect average risk, low-risk individuals may withdraw, raising the average risk of those remaining. Risk adjustment, subsidies, mandates and broad pooling can reduce this problem.

Moral hazard

Moral hazard occurs after insurance begins, when protection changes behaviour. It may involve increased service use, reduced preventive effort or provider responses to reimbursement incentives. Cost sharing can reduce low-value demand but may also deter high-value care, particularly for people with low income or chronic illness. Effective design therefore combines financial incentives with exemptions, clinical pathways and monitoring.

The principal–agent relationship

The patient is commonly the principal, and the clinician the agent who makes decisions on the patient’s behalf. The relationship is complicated because:

1. The agent has superior technical information.
2. The principal’s preferences and ability to pay may be incompletely known.
3. Outcomes are uncertain and may occur long after treatment.
4. The agent may have professional, financial and institutional objectives.

Agency is not inherently harmful. Delegation is valuable precisely because patients cannot efficiently acquire all clinical knowledge. The governance problem is aligning professional discretion with patient welfare through informed consent, guidelines, audit, transparency, payment reform and professional ethics.

Multiple agency relationships are common. A physician may act for the patient, the employing hospital, an insurer and a professional regulator simultaneously. Conflicts can arise when a hospital rewards volume while the insurer rewards cost control. Good governance makes objectives explicit and monitors outcomes rather than relying on trust alone.

5. Supplier-induced demand

Supplier-induced demand (SID) occurs when providers influence patients to consume more care than they would have chosen under fully informed, unbiased decision-making. The concept does not imply that every recommendation is inappropriate. Complex illness, new evidence and legitimate clinical discretion can produce more treatment without exploitation.

A useful conceptual model is:

where Q is observed quantity of care, Q^* is quantity consistent with informed patient preferences and clinical need, and I is the provider-induced component. This is not an identity that can be directly observed without assumptions; I must be inferred using evidence such as practice variation, incentives, appropriateness criteria and outcomes.

SID is more likely when patients cannot judge quality, provider income depends strongly on volume, competition is intense but price competition is constrained, and clinical uncertainty is high. It may be reduced by shared decision-making, second opinions, appropriateness standards, bundled payments, utilization review and public reporting.

A critical limitation is identification. High utilization may reflect sicker patients, better access, local preferences or superior diagnosis rather than inducement. Studies must control for risk, severity and case mix and should examine outcomes, not volume alone.

6. Transaction costs and institutional choice

Transaction costs are the costs of searching, negotiating, contracting, monitoring and enforcing an exchange. In healthcare they include referral coordination, credentialing, claims administration, data integration, quality monitoring and dispute resolution.

Ronald Coase’s institutional insight is that activities may be organized through markets, contracts or internal hierarchy depending on relative transaction costs. Oliver Williamson emphasized asset specificity, uncertainty and frequency. A hospital may employ specialists rather than contract with independent practices when coordination is critical, investments are specialized and contractual measurement is difficult.

Vertical integration can reduce duplication and improve care continuity, but it can also raise rivals’ costs, restrict referrals or create opportunities to charge facility fees. The relevant test is whether integration produces verifiable improvements in coordination, quality or cost that outweigh reduced competition.

7. Competition and the dimensions of performance

Competition should be evaluated across at least four dimensions.

Price and affordability

Market power can increase negotiated prices and patient financial burden. Yet low prices achieved by underpaying essential staff may damage quality. Managers should distinguish unit price, total episode cost and cost to the health system.

Access

Access includes availability, geographic proximity, appointment time, affordability, cultural acceptability and continuity. A merger may preserve a hospital locally but reduce specialist choice. Conversely, consolidation may keep an essential service open in a low-volume region.

Quality

Quality includes safety, effectiveness, timeliness, patient-centredness, equity and efficiency. Competition can improve quality when consumers and purchasers can observe meaningful outcomes. If quality is difficult to observe, providers may compete through amenities or marketing instead.

Innovation

Innovation includes new treatments, diagnostic methods, delivery models, workforce arrangements and digital systems. Large organizations may have capital and data advantages, while smaller entrants may experiment more rapidly. Intellectual property can reward research but may also delay diffusion through high prices or restrictive licensing.

A practical managerial framework is to evaluate any competitive change through the chain:

Figure: A structure–conduct–performance framework adapted to healthcare markets.

8. Consolidation and market power

Consolidation includes horizontal integration among hospitals or practices, vertical integration between providers and insurers or suppliers, and cross-market acquisitions across nearby but not identical services.

Potential benefits include economies of scale, shared information systems, stronger emergency capacity, clinical standardization and improved bargaining with suppliers. Potential harms include higher prices, reduced choice, foreclosure of competitors, reduced independent medical judgment and weaker incentives to improve.

The evaluation should be evidence-based:

1. Define the relevant product and geographic markets.
2. Measure concentration, but do not treat concentration as proof of harm.
3. Examine entry barriers, buyer power and substitutes.
4. Estimate effects on negotiated prices, premiums, access and quality.
5. Test claimed efficiencies for credibility, specificity and likely pass-through.
6. Consider remedies such as divestiture, contracting obligations, data portability or conduct restrictions.

A common concentration indicator is the Herfindahl–Hirschman Index (HHI):

where s_i is firm i’s market share expressed as a percentage, and the sum includes all firms. If shares are percentages, HHI ranges from close to 0 to 10,000; if shares are proportions, the equivalent index ranges from 0 to 1. Authorities use jurisdiction-specific thresholds and definitions, so HHI is a screening tool rather than a complete competition analysis.

Worked example

Suppose four hospitals have shares of 40%, 30%, 20% and 10%:

A merger between the two largest hospitals would produce shares of 70%, 20% and 10%:

The increase is 2,400 points. This large change would warrant detailed investigation, but the final judgment would still require analysis of entry, quality, efficiencies and local circumstances.

9. A detailed applied case

Illustrative case: The Meridian region hospital merger

Background. Meridian has two general hospitals, each approximately 25 minutes from most residents. Hospital A has 55% of inpatient admissions and Hospital B has 45%. Both negotiate separately with three insurers. The hospitals propose a merger, citing duplicated information systems, difficulty recruiting specialists and the need to finance a new cancer centre.

Problem. Insurers predict a substantial increase in negotiated prices. Community groups fear longer waits and reduced choice. The hospitals argue that the merger will improve quality and preserve services.

Analysis. The relevant market is likely regional inpatient care, although service-specific markets must also be considered. The pre-merger HHI is:

After the merger the market has one provider and HHI is 10,000, an increase of 4,950 points. This signals substantial structural risk. However, the analysis must ask whether a new entrant could build capacity, whether patients can travel to neighbouring regions, and whether insurers can credibly exclude the merged hospital from networks.

The claimed efficiencies are credible only if they are merger-specific and measurable. Shared information technology may be achievable through a service contract. A cancer centre may require integration, but its clinical benefits should be demonstrated through projected volumes, staffing and outcomes. The parties should provide a counterfactual: what happens without the merger?

Approach. The regulator requires an independent quality baseline, price and waiting-time data, and a plan for preserving emergency and safety-net services. It considers three options: prohibit the merger, approve it unconditionally, or approve it with enforceable remedies. Possible remedies include divesting a clinic, maintaining open access for competing specialists, prohibiting discriminatory contracting and publishing quality indicators.

Outcome. In this illustrative case, approval is conditional on a time-limited price-growth cap, open specialist privileges, interoperability requirements and independent monitoring of mortality, readmissions, waiting times and access by income group. The conditions are reviewed after three years.

Learning points. Concentration measures identify risk but do not prove harm. Efficiency claims must be specific and testable. Competition policy should consider quality and access, not only price. Remedies require measurable indicators, enforcement capacity and a credible counterfactual.

10. Technology, data and artificial intelligence

Digital platforms can lower search costs, support price comparison, coordinate referrals and enable remote care. They can also create new sources of market power through control of data, interoperability bottlenecks, proprietary algorithms and network effects. A platform becomes more valuable as more providers and patients use it, potentially producing rapid concentration.

Artificial intelligence may improve diagnostic accuracy, scheduling and risk stratification, but information advantages can become opaque. Managers should require validation in the relevant population, monitoring for bias, documentation of model limitations, human oversight, cybersecurity and clear accountability for errors. An algorithm’s predictive accuracy does not establish that acting on its prediction improves patient outcomes.

Data governance must address consent, lawful access, privacy, secondary use, security and commercial ownership. Interoperability can reduce switching costs and support competition, but standardization must not compromise safety or confidentiality.

11. Ethical, regulatory and managerial implications

Healthcare competition operates within professional and social obligations. Relevant ethical principles include beneficence, non-maleficence, respect for autonomy and justice. A financially attractive market strategy may be unacceptable if it systematically excludes vulnerable populations or encourages inappropriate treatment.

Managers should:

• define markets using patient pathways rather than organizational labels;
• monitor prices, total cost, outcomes, waiting times and equity together;
• separate legitimate clinical variation from inducement;
• design contracts with quality measures that are difficult to game;
• maintain conflict-of-interest policies and transparent referral rules;
• assess merger-specific efficiencies against a realistic counterfactual;
• protect patient choice, continuity and access during restructuring;
• use risk adjustment when comparing providers;
• involve clinicians and patients in governance;
• treat regulatory compliance as a minimum, not a substitute for ethical judgment.

Important limitations remain. Quality is multidimensional and imperfectly measured. Observed prices may reflect case mix and contractual discounts. Market boundaries change with technology and travel. Competition can improve efficiency but may also fragment care. Regulation can correct market failure but can itself create barriers to entry or administrative burden. Economic analysis should therefore combine quantitative evidence with institutional, clinical and distributional judgment.

Chapter Summary

Healthcare markets are shaped by uncertainty, insurance, specialized knowledge and the separation of decision-making from payment. Market structure influences provider conduct, but concentration alone does not determine outcomes. Monopolies may raise prices and restrict choice, while consolidation can also produce scale, coordination and investment benefits.

Information asymmetry creates adverse selection, moral hazard and principal–agent problems. Supplier-induced demand is a possible response to provider influence and incentives, but it must be distinguished from appropriate care and analysed with risk-adjusted evidence. Transaction-cost theory explains why healthcare activities are organized through markets, contracts or integrated organizations.

Competition should be assessed through price, access, quality, equity and innovation. HHI is a useful screening measure, not a complete welfare test. Effective management requires transparent data, careful contracting, ethical governance, attention to vulnerable populations and rigorous evaluation of technology and consolidation.

Key Terms

Market structure: The organization of buyers and sellers, including concentration, entry barriers and differentiation.

Derived demand: Demand for an input generated by demand for the final outcome, such as health.

Marginal cost: The additional cost of producing one more unit of output.

Monopoly: A market with one dominant seller.

Monopsony: A market with one dominant buyer.

Oligopoly: A market dominated by a small number of strategically interdependent firms.

Moral hazard: Behavioural change after insurance reduces exposure to financial risk.

Adverse selection: Risk-based participation caused by private information before contracting.

Information asymmetry: Unequal distribution of relevant information between parties.

Principal–agent relationship: A relationship in which one party delegates decisions to another.

Supplier-induced demand: Additional utilization influenced by providers beyond informed patient choice.

Transaction costs: Costs of searching, negotiating, monitoring and enforcing exchange.

Vertical integration: Combining organizations at different stages of production or financing.

Horizontal integration: Combining organizations operating at the same market level.

Market power: Ability to influence price, quantity, quality or contractual terms.

HHI: Sum of squared percentage market shares used as a concentration indicator.

Risk adjustment: Statistical adjustment for differences in expected patient cost or severity.

Network effects: Increased value of a platform as participation expands.

Review Questions

Short Answer Questions

1. Why is perfect competition an unrealistic but useful benchmark in healthcare?
2. Distinguish moral hazard from adverse selection.
3. What is the principal–agent problem in clinical care?
4. Define transaction costs and give two healthcare examples.
5. Why should HHI not be treated as proof that a merger is harmful?

Long Answer Questions

1. Explain how insurance changes healthcare demand and discuss the policy tension between financial protection and overuse.
2. Analyse supplier-induced demand, including its causes, possible remedies and identification challenges.
3. Compare monopoly, oligopoly and monopsony in terms of price, access, quality and innovation.
4. Explain how vertical integration may both improve coordination and create competition concerns.
5. Discuss how information asymmetry affects clinical quality and the design of healthcare regulation.

Analytical / Application Questions

1. A regional market has hospital shares of 50%, 25%, 15% and 10%. Calculate the HHI and explain what additional evidence would be needed before evaluating a proposed merger.
2. An insurer introduces a high deductible that reduces imaging use but increases delayed cancer diagnoses among low-income patients. Analyse the policy using moral hazard, equity and value-of-care concepts.
3. A hospital-owned physician group sharply increases referrals for profitable procedures. Design an investigation that distinguishes supplier-induced demand from appropriate treatment of a sicker patient population.

Multiple Choice Questions with Answers

Question 1

Which feature most clearly distinguishes healthcare markets from the standard competitive model?

A. Healthcare has no production costs.

B. Patients always possess complete clinical information.

C. Clinical knowledge is specialized and demand is uncertain.

D. All healthcare services are homogeneous.

Correct Answer: C. Clinical knowledge is specialized and demand is uncertain.

Question 2

Adverse selection occurs primarily when private information affects behaviour:

A. After a claim has been paid

B. Before an insurance contract is formed

C. Only after a merger

D. Only when prices are regulated

Correct Answer: B. Before an insurance contract is formed

Question 3

A principal–agent problem in healthcare exists because:

A. Patients always know more than clinicians

B. Clinicians make decisions on behalf of less-informed patients

C. Insurers provide all clinical services

D. Hospitals cannot employ professionals

Correct Answer: B. Clinicians make decisions on behalf of less-informed patients

Question 4

Using percentage market shares, what is the HHI for firms with shares of 50%, 30% and 20%?

A. 1,000

B. 2,900

C. 3,800

D. 10,000

Correct Answer: B. 2,900

Question 5

Which is the best interpretation of supplier-induced demand?

A. All provider-recommended care is inappropriate

B. Providers may influence utilization beyond informed patient choice

C. Patients never influence treatment decisions

D. Demand is induced only by insurers

Correct Answer: B. Providers may influence utilization beyond informed patient choice

Question 6

Which factor is most likely to increase transaction costs in healthcare?

A. Simple standardized services

B. Perfectly observable outcomes

C. Complex coordination and difficult quality monitoring

D. No need for contracting

Correct Answer: C. Complex coordination and difficult quality monitoring

Question 7

A monopsony is characterized by:

A. One dominant buyer

B. One dominant seller

C. Many identical sellers and buyers

D. No barriers to entry

Correct Answer: A. One dominant buyer

Question 8

Which is a potential benefit of provider consolidation?

A. Guaranteed lower prices in every case

B. Improved coordination and economies of scale

C. Elimination of all information asymmetry

D. Automatic improvement in equity

Correct Answer: B. Improved coordination and economies of scale

Question 9

Moral hazard may arise when insurance:

A. Makes covered care financially less costly at the point of use

B. Eliminates all clinical uncertainty

C. Prevents anyone from seeking care

D. Requires risk adjustment

Correct Answer: A. Makes covered care financially less costly at the point of use

Question 10

Why is concentration an incomplete measure of healthcare competition?

A. Concentration never affects prices

B. It ignores entry, buyer power, quality and efficiency evidence

C. It measures only patient satisfaction

D. It applies only to pharmaceutical markets

Correct Answer: B. It ignores entry, buyer power, quality and efficiency evidence